Skip to main content
Signal8

Pharmadrug Inc. (LMLLF)

Sector: Drug Manufacturers - Specialty & Generic

Industry: Drug Manufacturers - Specialty & Generic

Pharmadrug Inc. logo

Pharmadrug Inc.

OTC:LMLLFHealthcare
+65.29%$0.0060
CLOSED
Mkt Cap$805K
EV-
Float132.83M
O/S134.21M
VOL2K sh
$ Vol$11
RVOL2.08×
Inst Own-
Net Cash/Sh-
Dilution
Pharmadrug Inc. logoOTC:LMLLFClosed$0.0060+65.29%
Historical Data
DateOpenHighLowCloseVolume
Nov 11, 20260.00600.00600.00600.00601,897
Oct 29, 20260.00430.00430.00360.00361,642
Oct 27, 20260.00330.00410.00330.0035398
Oct 21, 20260.00340.00340.00340.0034142
Oct 20, 20260.00430.00430.00430.0043571
Oct 19, 20260.00330.00430.00330.0043821
Oct 15, 20260.00430.00430.00430.0043428
Oct 12, 20260.00420.00420.00420.0042328
Oct 9, 20260.00410.00410.00410.00413,000
Oct 8, 20260.00440.00440.00440.00441,463
Analyst Coverage
No analyst coverage for this companyNo ratings, price targets, or covering firms on file.
About

Pharmadrug Inc. operates as a specialized pharmaceutical company, primarily dedicated to the exploration, development, and commercialization of controlled substances and naturally derived therapeutic agents.

Its portfolio encompasses novel compounds like psychedelics and cannabis, alongside other naturally sourced approved medicines. Beyond its core research and development activities, the firm plays a crucial role in importing and distributing medical cannabis to pharmacies across Germany and the broader European Union.

The company also oversees Super Smart, an initiative focused on promoting and exploring the benefits of functional and psilocybin mushrooms.

Additionally, Pharmadrug actively engages in researching and enhancing established natural remedies. Significant research collaborations underpin its innovative pipeline, including an agreement with the University of Michigan to assess N, N-dimethyltryptamine's (DMT) role in various conscious states. Another partnership with the Southwest Research Institute is geared towards the non-clinical and clinical manufacturing of cepharanthine. Furthermore, a clinical trial agreement with Johns Hopkins University facilitates a study comparing the acute and enduring psychological and neural effects of DMT against an undisclosed, highly active comparator molecule. Headquartered in Toronto, Canada, the company adopted its current name, Pharmadrug Inc., in October 2019, having previously operated as Aura Health Inc.

Key Metrics
Market Cap$805,284
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--

based on 134.21M shares outstanding

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ExchangeOTC
CountryCACA
IPO Date-
Shares Outstanding134.21M
Authorized Shares
Float132.83M
52-Week Range
$0.0024$0.0170
$0.0060(25th percentile)
Volume
Average Daily Volume912
1.90K today vs 912 avg(+108%)

30d Avg

912

60d Avg

3.32K

90d Avg

5.49K

Earnings
Dividend History
No dividend history available

Pharmadrug Inc. (OTC: LMLLF) traded at $0.0060 on Nov 11, 2026, up 65.29% from the previous close of $0.0036. 52-week range: $0.0024 to $0.0170. The company is in the Healthcare sector (Drug Manufacturers - Specialty & Generic).